Biopharmaceutical group Ablynx has made some changes to its board of directors after recently declining a takeover proposal for the second time from Novo Nordisk.
Heading up the board is Ablynx’s non-executive director Dr Bo Jesper Hensen (pictured), who was unanimously elected as its new chairman.
He succeeds Dr Peter Fellner – who has served as chairman since 2013 but resigned with immediate effect shortly after the company turned down Novo’s unsolicited offer.
Dr Hensen’s expertise lies in orphan drug research and development, international marketing and commercialisation and has experience in regulatory, pharmacovigilance, medical marketing and business development knowledge.
Dr Edwin Moses, chief executive officer at Ablynx, said: “We are very fortunate to have an extremely suitable successor with Bo Jesper, allowing for an orderly transition at this important time.
“Hensen is the ideal person to lead the board moving forward and his wealth of experience is particularly relevant as we advance towards the potential approvals and global launches of our lead, wholly-owned product, caplacizumab, in addition to advancing our extensive pipeline.”
Source: PM Live
Sequana, a company focusing on liver disease, heart failure and cancer has announced positive top-line results from SAHARA – the phase 2a study using its first-generation direct sodium removal (DSR) product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients confirmed long-lasting clinical benefits.
Bristol Myers Squibb has officially opened its Cruiserath Biologics site in Dublin. The site, which represents a $1bn investment – was officially opened by the company’s chief executive officer, Giovanni Caforio, who arrived from New York, and site general manager Pádraig Keane.
Like it or loathe it, and whatever its new direction, Twitter is still a powerful platform for doctors, and pharma should not abandon the troubled social media site yet, according to a new report from healthcare consultants at ZoomRx.